Can HCV Core Ag Testing Replace the Routine Screening Assays in Patients on Hemodialysis?

authors:

avatar Behzad Einollahi 1 , avatar Neda Raeessi 2 , * , avatar Fereshteh Raeessi 3

Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Atherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Clinical Research Center, Azad University of Pharmacy, Tehran, IR Iran

how to cite: Einollahi B, Raeessi N, Raeessi F. Can HCV Core Ag Testing Replace the Routine Screening Assays in Patients on Hemodialysis?. Hepat Mon. 2014;14(7):e16371. https://doi.org/10.5812/hepatmon.16371.

Acknowledgements

References

  • 1.

    Moini M, Ziyaeyan M, Aghaei S, Sagheb MM, Taghavi SA, Moeini M, et al. Hepatitis C virus (HCV) Infection Rate among Seronegative Hemodialysis Patients Screened by Two Methods; HCV Core Antigen and Polymerase Chain Reaction. Hepat Mon. 2013;13(6). ee9147. [PubMed ID: 24032048]. https://doi.org/10.5812/hepatmon.9147.

  • 2.

    Alavian SM. Diabetes, renal failure and hepatitis C infection: The puzzle should be attended more in future. Nephro Urol Mon.;.

  • 3.

    Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar M, Ahrabi S. Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. Nephrology (Carlton). 2003;8(5):256-60. [PubMed ID: 15012714].

  • 4.

    Elamin S, Abu-Aisha H. Prevention of hepatitis B virus and hepatitis C virus transmission in hemodialysis centers: review of current international recommendations. Arab J Nephrol Transplant. 2011;4(1):35-47. [PubMed ID: 21469594].

  • 5.

    Nemati E, Alavian SM, Taheri S, Moradi M, Pourfarziani V, Einollahi B. Hepatitis C virus infection among patients on hemodialysis: a report from a single center in Iran. Saudi J Kidney Dis Transpl. 2009;20(1):147-53. [PubMed ID: 19112238].

  • 6.

    Hajarizadeh B, Einollahi B, Alavian S, Nafar M. Prevalence of Hepatitis c virus (HCV) infection and related risk factors among Iranian patients on hemodialysis. Am J Infec Con. 2005;33(5):93-4. https://doi.org/10.1016/j.ajic.2005.04.113.

  • 7.

    Li Cavoli G, Zagarrigo C, Schillaci O, Servillo F, Tralongo A, Coglitore M, et al. Hepatitis C virus core antigen test in monitoring of dialysis patients. Hepat Res Treat. 2012;2012:832021. [PubMed ID: 23304475]. https://doi.org/10.1155/2012/832021.

  • 8.

    KDIGO clinical practice guideline for the diagnosis e, prevention, and treatment of Chronic Kidney Disease. Guideline 1: Detection and evaluation of HCV in CKD. Offic J Inter Soci Nephrol. 2008;73(109):10-9.

  • 9.

    Veillon P, Payan C, Picchio G, Maniez-Montreuil M, Guntz P, Lunel F. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy. J Clin Microbiol. 2003;41(7):3212-20. [PubMed ID: 12843066].

  • 10.

    Kato A, Takita T, Furuhashi M, Fujimoto T, Suzuki H, Maruyama Y, et al. Association of HCV core antigen seropositivity with long-term mortality in patients on regular hemodialysis. Nephron Extra. 2012;2(1):76-86. [PubMed ID: 22619670]. https://doi.org/10.1159/000337333.